Drugs / INGN 241
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00116363 | Mar 2005 → Dec 2006 | melanoma, metastatic neoplasm | Introgen Therapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INGN 241 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00116363 ↗ |
| Known as | Ad-mda7 | “Phase II Study Examining the Biological Efficacy of Intratumoral INGN 241 (Ad-mda7) Administration in Patients With In Transit Melanoma” NCT00116363 ↗ |
| Route | Other | “intratumoral administration” NCT00116363 ↗ |